161 related articles for article (PubMed ID: 7649284)
1. Proposed cation-pi mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition.
Lin Z; Johnson ME
FEBS Lett; 1995 Aug; 370(1-2):1-5. PubMed ID: 7649284
[TBL] [Abstract][Full Text] [Related]
2. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition.
Brandstetter H; Kühne A; Bode W; Huber R; von der Saal W; Wirthensohn K; Engh RA
J Biol Chem; 1996 Nov; 271(47):29988-92. PubMed ID: 8939944
[TBL] [Abstract][Full Text] [Related]
3. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
Rezaie AR
Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
[TBL] [Abstract][Full Text] [Related]
4. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
5. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
7. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
8. Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach.
Rao MS; Olson AJ
Proteins; 1999 Feb; 34(2):173-83. PubMed ID: 10022353
[TBL] [Abstract][Full Text] [Related]
9. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
[TBL] [Abstract][Full Text] [Related]
10. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
11. DX-9065a, a direct inhibitor of factor Xa.
Kaiser B
Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydro-isoquinoline-based factor Xa inhibitors.
Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W
J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616
[TBL] [Abstract][Full Text] [Related]
13. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
Katakura S; Nagahara T; Hara T; Iwamoto M
Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
[TBL] [Abstract][Full Text] [Related]
14. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1.
Schweinitz A; Stürzebecher A; Stürzebecher U; Schuster O; Stürzebecher J; Steinmetzer T
Med Chem; 2006 Jul; 2(4):349-61. PubMed ID: 16848746
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Nagamochi M; Kobayashi S; Komoriya S; Yokomizo A; Muto R; Yamaguchi M; Osanai K; Suzuki M; Kanno H
Bioorg Med Chem; 2009 Feb; 17(3):1193-206. PubMed ID: 19128974
[TBL] [Abstract][Full Text] [Related]
16. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Becker RC; Alexander J; Dyke CK; Harrington RA
Thromb Haemost; 2004 Dec; 92(6):1182-93. PubMed ID: 15583722
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
18. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of human factor Xa complexed with potent inhibitors.
Maignan S; Guilloteau JP; Pouzieux S; Choi-Sledeski YM; Becker MR; Klein SI; Ewing WR; Pauls HW; Spada AP; Mikol V
J Med Chem; 2000 Aug; 43(17):3226-32. PubMed ID: 10966741
[TBL] [Abstract][Full Text] [Related]
20. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]